• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.

作者信息

Jen Wei-Ying, Loghavi Sanam, Bazinet Alexandre, Bataller Alex, Bouligny Ian, Daver Naval G, Issa Ghayas C, Arani Naszrin, Almanza Huante Emmanuel, Maiti Abhishek, Montalban-Bravo Guillermo, Borthakur Gautam, Short Nicholas J, Pierce Sherry, Jabbour Elias, Garcia-Manero Guillermo, Ravandi Farhad, Kantarjian Hagop M, DiNardo Courtney D, Kadia Tapan M

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2025 Aug 28. doi: 10.1002/ajh.70046.

DOI:10.1002/ajh.70046
PMID:40874710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12430535/
Abstract
摘要

相似文献

1
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies.采用维奈克拉为基础的疗法治疗NPM1突变型急性髓系白血病的复发结局及模式
Am J Hematol. 2025 Aug 28. doi: 10.1002/ajh.70046.
2
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.在接受异基因干细胞移植的患者中，与强化化疗相比，用克拉屈滨/低剂量阿糖胞苷/维奈托克进行低强度治疗在老年急性髓系白血病患者中具有更好的效果。
Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29.
3
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis. Venetoclax 联合治疗与其他治疗方案在不适合强化化疗的初治急性髓系白血病患者中的疗效比较：一项网络荟萃分析。
Value Health. 2023 Dec;26(12):1689-1696. doi: 10.1016/j.jval.2023.09.001. Epub 2023 Sep 21.
4
Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.基于 venetoclax 的联合疗法治疗未经治疗的急性髓系白血病的疗效和安全性：一项荟萃分析。
Hematology. 2024 Dec;29(1):2343604. doi: 10.1080/16078454.2024.2343604. Epub 2024 May 4.
5
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.文森特：一项随机对照试验，评估维奈克拉联合阿扎胞苷与强化化疗在新诊断的、NPM1突变型急性髓系白血病患者中的疗效。
Ann Hematol. 2025 Jul 9. doi: 10.1007/s00277-025-06496-7.
6
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study.急性髓系白血病中维奈托克临床结局的遗传和表型相关性：GEN-PHEN-VEN研究
Blood Cancer Discov. 2025 May 21. doi: 10.1158/2643-3230.BCD-24-0256.
7
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.维奈托克联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项关于适应证特异性分层、分子标志物和血液学毒性的多中心真实世界研究
Cancer Cell Int. 2025 Jul 1;25(1):241. doi: 10.1186/s12935-025-03858-z.
8
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.不适合标准诱导化疗的急性髓细胞白血病患者的治疗方法：系统评价。
Future Oncol. 2023 Apr;19(11):789-810. doi: 10.2217/fon-2022-1286. Epub 2023 May 12.
9
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.对于不符合强化化疗条件的异柠檬酸脱氢酶（IDH）突变型急性髓系白血病（AML）患者，采用去甲基化药物、维奈克拉和异柠檬酸脱氢酶抑制剂的一线三联方案的疗效。
J Clin Oncol. 2025 Aug 20;43(24):2692-2699. doi: 10.1200/JCO-25-00640. Epub 2025 Jun 13.
10
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.维奈克拉治疗新诊断、复发或难治性急性髓系白血病患者的临床经验。
J Cancer Res Clin Oncol. 2022 Nov;148(11):3191-3202. doi: 10.1007/s00432-022-03930-5. Epub 2022 Jan 31.

本文引用的文献

1
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.维奈托克联合FLAG-IDA诱导和巩固治疗新诊断、复发或难治性急性髓系白血病的长期结果
Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25.
2
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.NPM1 突变型 AML 的分子、临床和治疗学决定因素。
Blood. 2024 Aug 15;144(7):714-728. doi: 10.1182/blood.2024024310.
3
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.分子 MRD 对接受维奈托克为基础的非强化治疗的 NPM1 突变 AML 患者具有很强的预后价值。
Blood. 2024 Jan 25;143(4):336-341. doi: 10.1182/blood.2023021579.
4
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.伴有或不伴有吉妥珠单抗奥唑米星的强化化疗治疗 NPM1 突变型急性髓系白血病（AMLSG 09-09）：一项随机、开放标签、多中心、3 期临床试验。
Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12.
5
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Venetoclax 联合克拉屈滨联合低剂量阿糖胞苷与 5-阿扎胞苷交替治疗新诊断的老年急性髓系白血病的 II 期研究。
J Clin Oncol. 2022 Nov 20;40(33):3848-3857. doi: 10.1200/JCO.21.02823. Epub 2022 Jun 15.
6
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Venetoclax 联合克拉屈滨、伊达比星和阿糖胞苷强化化疗治疗初诊急性髓系白血病或高危骨髓增生异常综合征患者：来自单中心、单臂、2 期临床试验的一个队列研究。
Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
7
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
8
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.伴有 NPM1 突变的急性髓系白血病的克隆进化模式。
Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.
9
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
10
Genomic Classification and Prognosis in Acute Myeloid Leukemia.急性髓系白血病的基因组分类与预后
N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.